Sei Investments Co. grew its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,504,503 shares of the medical equipment provider's stock after purchasing an additional 101,542 shares during the period. Sei Investments Co. owned about 0.67% of Hologic worth $108,460,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. General Partner Inc. bought a new position in shares of Hologic during the 4th quarter valued at $26,000. Groupama Asset Managment boosted its position in Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC grew its stake in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares during the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.
Hologic Stock Up 1.4 %
Hologic stock traded up $0.84 on Thursday, hitting $62.32. 1,303,646 shares of the stock traded hands, compared to its average volume of 1,751,573. The business's fifty day simple moving average is $65.56 and its 200 day simple moving average is $73.57. The firm has a market cap of $13.98 billion, a P/E ratio of 19.66, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1 year low of $60.34 and a 1 year high of $84.67.
Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages have commented on HOLX. Royal Bank of Canada decreased their price target on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Jefferies Financial Group assumed coverage on shares of Hologic in a research note on Tuesday, December 10th. They issued a "hold" rating and a $85.00 target price on the stock. Evercore ISI dropped their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research report on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Finally, Morgan Stanley dropped their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $84.62.
Check Out Our Latest Report on Hologic
About Hologic
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
See Also
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
